Breast cancer research program

Active Awarded Last action

Contract number
HT942726FE020
Awardee
Awarding agency
Obligated
$439,016

Award facts

Contract value 70% obligated
$631,610.06 Current and potential, with all options
Completion date 50% complete
Current and potential, with all options
Contracting staff
NAICS code
541990 All Other Professional, Scientific, and Technical Services
PSC
R408 Support- Professional: Program Management/Support
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Reston, VA 20190, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The Defense Health Agency issued a delivery order to Leidos, Inc. on May 16, 2026, for the Breast Cancer Research Program with a ceiling value of $631,610.06 and an ultimate completion date of March 31, 2027.

Place of performance is Reston, VA. The order is priced on a cost-plus-fixed-fee basis with no set-aside designation. The source does not identify a parent IDIQ or GWAC vehicle for this delivery order.

Quick answers

Who was awarded contract HT942726FE020?

HT942726FE020 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on May 16, 2026.

How much is contract HT942726FE020 worth?

The government has obligated $439,016 on HT942726FE020. Its current value, with exercised options, is $631,610.

Is contract HT942726FE020 an order under another contract?

Yes. HT942726FE020 is a delivery order under HT942523D0002, an indefinite delivery contract.

Was contract HT942726FE020 competed?

The extent of competition for HT942726FE020 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login